Evidence map›Paper›PMID 40371428›Full record

ReviewCentral European journal of urology2025

The potential of gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography as a main diagnostic tool in prostate cancer staging.

Oleksii Pisotskyi, Piotr Petrasz, Piotr Zorga, Marcin Gałęski, Paweł Szponar, Krzysztof Koper, Katarzyna Brzeźniakiewicz-Janus, Tomasz Drewa, Krzysztof Kaczmarek, Michał Cezary Czarnogórski and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Central European journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Oleksii Pisotskyi *Urology and Urological Oncology Department, Multidisciplinary Regional Hospital, Gorzow Wielkopolski, Poland.
Piotr Petrasz *Urology and Urological Oncology Department, Multidisciplinary Regional Hospital, Gorzow Wielkopolski, Poland.
Piotr ZorgaDepartment and Chair of Urology and Andrology, University Hospital No. 1 in Bydgoszcz, Ludwik Rydygier's Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland.
Marcin GałęskiUrology and Urological Oncology Department, Multidisciplinary Regional Hospital, Gorzow Wielkopolski, Poland.
Paweł SzponarUrology and Urological Oncology Department, Multidisciplinary Regional Hospital, Gorzow Wielkopolski, Poland.
Krzysztof KoperClinical Oncology and Nursing Department, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.
Katarzyna Brzeźniakiewicz-JanusHaematology, Oncology, and Radiotherapy Department and Clinic, University of Zielona Gora, Multidisciplinary Regional Hospital, Gorzow Wielkopolski, Poland.
Tomasz DrewaDepartment and Chair of Urology and Andrology, University Hospital No. 1 in Bydgoszcz, Ludwik Rydygier's Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland.
Krzysztof KaczmarekUrology and Urological Oncology Department, Multidisciplinary Regional Hospital, Gorzow Wielkopolski, Poland.
Michał Cezary CzarnogórskiDepartment and Chair of Urology and Andrology, University Hospital No. 1 in Bydgoszcz, Ludwik Rydygier's Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland.
Jan AdamowiczDepartment and Chair of Urology and Andrology, University Hospital No. 1 in Bydgoszcz, Ludwik Rydygier's Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Prostate cancer (PC) remains a significant global health burden, necessitating accurate staging for optimal treatment planning. Conventional imaging methods, including multiparametric magnetic resonance imaging (mpMRI), computed tomography (CT), and bone scintigraphy (BS), exhibit limitations in sensitivity and specificity. Gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography ( Material and methods: A comprehensive review of current literature was conducted to assess the role of Results: Conclusions:

Indexed as

68Ga PSMA-PET/CTimagin comparisonprostate cancerstaging accuracy

Identifiers

PMID40371428
PMCPMC12073512

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.